Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes

Abstract Background Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Inflammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. Methods Whether omarigliptin...

Full description

Bibliographic Details
Main Author: Sachiko Hattori
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Omarigliptin
Once-weekly DPP4 inhibitor
High-sensitivity C-reactive protein
Insulin resistance
Online Access:http://link.springer.com/article/10.1186/s13098-020-00533-3

Internet

http://link.springer.com/article/10.1186/s13098-020-00533-3

Similar Items